Timothy Larson, MD
Hand Surgery · Denton, TXNPI 1144434242
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,563 of the $9,337 with a category attached, or 81.0%. Osteomed LLC accounts for 81.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $8,090 and has fallen 98.5% since, to $121 in 2025.
Across 60 payments — averaging $155.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Osteomed LLC$8K
- Endo Pharmaceuticals Inc.$416
- Stryker$410
- Johnson & Johnson$291
- Pylant Medical$195
- Integra Lifesciences Corporation$114
- plus $348 from 9 others
What the payments were for
- Consulting fees$7,56381%
- Food & beverage$1,77419%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Osteomed LLC | 2 | $7,563 |
| Endo Pharmaceuticals Inc. | 10 | $416 |
| Stryker | 16 | $410 |
| Johnson & Johnson | 9 | $291 |
| Pylant Medical | 5 | $195 |
| Integra Lifesciences Corporation | 5 | $114 |
| Acumed LLC | 2 | $89 |
| Amgen(2 entities) | 3 | $73 |
| Orthofix Medical, Inc. | 2 | $52 |
| DJO, LLC | 1 | $31 |
| Ossur Americas, Inc. | 1 | $28 |
| Smith+Nephew | 1 | $23 |
| Sonex Health, Inc. | 1 | $21 |
| Endo USA, Inc. | 1 | $18 |
| Bioventus LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,337 in reported general payments places this provider in the 65th percentile of 170 hand surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 61 | $888 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 63 | $396 |
| Cephalexin | 56 | $263 |
| Meloxicam | 74 | $217 |
| Diclofenac Sodium | 14 | $130 |
| Tramadol Hcl | 15 | $24 |
Paid to pharmacies, not to this prescriber.
Other hand surgery in Denton
- David RingAustin$536K
- Kourosh JafarniaHouston$278K
- Brendan MackayLubbock$274K
- John FaillaceWoodway$212K
- Daniel KoehlerDallas$208K
- Timothy NiacarisArlington$160K
- Steven NiedermeierArlington$152K
- William PientkaFort Worth$113K
- Ann GoldenDallas$107K
- Cameron AtkinsonArlington$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.